Skip to main content
. 2020 Mar 12;1(2):100024. doi: 10.1016/j.jtocrr.2020.100024

Figure 2.

Figure 2

Progression-free and overall survival for study cohort of patients with limited-stage SCLC. (A) Progression-free survival of the cohort of patients in whom we ever detected circulating tumor DNA (ctDNA) after definitive therapy (n = 15, blue line) versus never detected ctDNA after definitive therapy (n = 8, red line). (B) Overall survival of the cohort of patients in whom we ever detected ctDNA after definitive therapy (n = 15, blue line) versus never detected ctDNA after definitive therapy (n = 8, red line). LS-SCLC, limited-stage SCLC.